Predicting glioblastoma molecular subtypes and prognosis with a multimodal model integrating convolutional neural network, radiomics, and semantics
Sheng Zhong,Jia-Xin Ren,Ze-Peng Yu,Yi-Da Peng,Cheng-Wei Yu,Davy Deng,YangYiran Xie,Zhen-Qiang He,Hao Duan,Bo Wu,Hui Li,Wen-Zhuo Yang,Yang Bai,Ke Sai,Yin-Sheng Chen,Cheng-Cheng Guo,De-Pei Li,Ye Cheng,Xiang-Heng Zhang,Yong-Gao Mou
DOI: https://doi.org/10.3171/2022.10.jns22801
IF: 5.408
2022-12-01
Journal of Neurosurgery
Abstract:OBJECTIVE The aim of this study was to build a convolutional neural network (CNN)–based prediction model of glioblastoma (GBM) molecular subtype diagnosis and prognosis with multimodal features. METHODS In total, 222 GBM patients were included in the training set from Sun Yat-sen University Cancer Center (SYSUCC) and 107 GBM patients were included in the validation set from SYSUCC, Xuanwu Hospital Capital Medical University, and the First Hospital of Jilin University. The multimodal model was trained with MR images (pre- and postcontrast T1-weighted images and T2-weighted images), corresponding MRI impression, and clinical patient information. First, the original images were segmented using the Multimodal Brain Tumor Image Segmentation Benchmark toolkit. Convolutional features were extracted using 3D residual deep neural network (ResNet50) and convolutional 3D (C3D). Radiomic features were extracted using pyradiomics. Report texts were converted to word embedding using word2vec. These three types of features were then integrated to train neural networks. Accuracy, precision, recall, and F1-score were used to evaluate the model performance. RESULTS The C3D-based model yielded the highest accuracy of 91.11% in the prediction of IDH1 mutation status. Importantly, the addition of semantics improved precision by 11.21% and recall in MGMT promoter methylation status prediction by 14.28%. The areas under the receiver operating characteristic curves of the C3D-based model in the IDH1 , ATRX, MGMT , and 1-year prognosis groups were 0.976, 0.953, 0.955, and 0.976, respectively. In external validation, the C3D-based model showed significant improvement in accuracy in the IDH1 , ATRX, MGMT , and 1-year prognosis groups, which were 88.30%, 76.67%, 85.71%, and 85.71%, respectively (compared with 3D ResNet50: 83.51%, 66.67%, 82.14%, and 70.79%, respectively). CONCLUSIONS The authors propose a novel multimodal model integrating C3D, radiomics, and semantics, which had a great performance in predicting IDH1 , ATRX, and MGMT molecular subtypes and the 1-year prognosis of GBM.
surgery,clinical neurology